Publication | Open Access
Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
28
Citations
0
References
2019
Year
Anti–pd-1/l1 TherapyMedicineImmunologyPathologyImmune Checkpoint InhibitorIi StudyCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology
No additional data available for this publication yet. Check back later!